nidan7500 Thursday, 11/29/18 10:52:23 AM Re: XenaLives post# 173268 Post # of 232071 Quote:Within a year of approval Anavex could also be a major player, if not dominant, in the CNS and psychiatric space. Totally agree w/this assessment. IMO, the PDD trials w/end points which are quickly and dramatically demonstrated show the level of planning and brilliance of the AVXL plans. CNS disease trials are known to go on forever.When we have connected a few dots w/PDD followed by RS our credibility should follow higher. When Biomarkers follow for AD as those trials proceed then more dots can be connected. We can say that if we can figure it out on this MB then (at least) it looks like there is a plan. It may be understandable and justified that AVXL keeps off the horizon w/it's product plans/charts, but I still do not like these marginal conditions. Unless and until some Biomarker(s) science is quickly proven we are tied to a proof by endless trial methodology (read LONG time). (that has to change if we want to beat this CNS death watch) My guess is a big part of Dr.M plan involves defining and demonstrating CNS cellular homeostasis for each indication so that trials become the method for long term validation/proof that correct treatments (w/o unintended consequences) not that the indicated treatment is effective . IMO, PDD w/ short term end points are a bet the company move, same for RS. we'll see. By the time we get sequenced to AD trial results expectations will be higher.